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Background: The aim of the study was to determine the most common pharmacological strategies used in the
management of major depressive disorder (MDD) after an inadequate response to first-line antidepressant
treatment in clinical practice.
Methods: Multicenter, non-interventional study in adult outpatients with a DSM-IV-TR diagnosis of MDD and
inadequate response to first-line antidepressant medication. Multiple logistic regression analyses were performed to
identify independent factors associated with the adoption of a specific second-line strategy.
Results: A total of 273 patients were analyzed (mean age: 46.8 years, 67.8% female). Baseline mean
Montgomery-Asberg Depression Rating Scale total score was 32.1 (95%CI 31.2-32.9). The most common strategies
were: switching antidepressant medication (39.6%), augmentation (18.8%), and combination therapy (17.9%).
Atypical antipsychotic drugs were the most commonly used agent for augmenting antidepressant effect. The
presence of psychotic symptoms and the number of previous major depressive episodes were associated with the
adoption of augmenting strategy (OR = 3.2 and 1.2, respectively).
Conclusion: The switch to another antidepressant agent was the most common second-line therapeutic approach.
Psychiatrists chose augmentation based on a worse patients’ clinical profile (number of previous episodes and
presence of psychotic symptoms).
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Major depression is one of the most prevalent mental
disorders in Europe, with an estimated prevalence of
6.9% [1]. According to some projections, major depres-
sive disorder (MDD) will be one of the three leading
causes of burden of disease in 2030 [2].
Despite the introduction of newer-generation antide-
pressants, approximately 50% of patients experience
non-response to treatment with a first-line antidepres-
sant [3,4]. The presence of residual symptoms has been
associated with a higher risk of recurrence, more chronic
depressive episodes, a shorter duration between episodes,
and a worse functioning [5-7]. In addition, not achieving* Correspondence: jorgealejandro.maurino@astrazeneca.com
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distribution, and reproduction in any mediumsymptomatic remission increases the economic burden
of this mental disorder which is mainly explained by loss
of productivity due to disability and absenteeism and to
the use of healthcare resources such as medical visits and
pharmacological therapies [8-11].
Current guidelines recommend four pharmacological
strategies for the management of partial response or non-
response of MDD: increasing the dose of the antidepres-
sant, switching to a different antidepressant, augmenting
the treatment regimen with a non-antidepressant agent
such as lithium, atypical antipsychotic drugs or thyroid
hormones, or combining the initial antidepressant with a
second antidepressant [12]. However, the evidence to give
clear recommendations regarding the optimal stepwise
pharmacological approach after inadequate response to
first-line antidepressant treatment remains limited
[4,13-15]. Several factors should be considered whentral Ltd. This is an Open Access article distributed under the terms of the
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of partial benefit from the first-line AD and/or the risk of
withdrawal symptoms when switching agents, the risk of
drug interactions, tolerability and adherence issues with
combination and augmentation strategies [4].
In part due to the lack of clear recommendations,
there is considerable heterogeneity in real clinical prac-
tice in terms of how and when to adopt a new pharma-
cological approach in those patients who have not
responded adequately to first-line treatment. Moreover,
little is known regarding factors influencing physician
choice among the four proposed strategies.
The primary aim of the study was to determine the
most common pharmacological strategies for MDD
patients after initial antidepressant treatment failure in
clinical practice. In addition, we explored the relationship
between sociodemographic and clinical characteristics
and the likelihood of a switching, augmentation or com-
bination strategy being adopted by the psychiatrist.Methods
This was a 6 months, non-interventional study con-
ducted in 60 community mental health centres through-
out Spain. The study was approved by the institutional
review board of the Fundació Catalana d´Hospitals
(Barcelona, Spain; NCT00782964).
Male or female patients aged 18 or above with a Diag-
nostic and Statistical Manual of Mental Disorders,
Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of
major depressive disorder (MDD), single or recurrent
episode, were eligible for inclusion. Participants were
outpatients meeting the following criteria: a history of
inadequate response (partial or non-response) during
the current episode to first-line treatment with a select-
ive serotonin reuptake inhibitor (SSRI) or a selective
serotonin-norepinephrine reuptake inhibitor (SNRI),
which was given for at least 6 weeks at adequate doses
according to the label. Exclusion criteria included: dur-
ation of current MDD episode > 12 months or < 4 weeks,
and clinically significant medical illness. Written
informed consent was obtained once the study had been
fully described to the participants.
Sociodemographic and clinical data, as well as the new
pharmacological strategy adopted, were collected from
medical records and clinical interviews. The study proto-
col did not pre-specify any particular therapy. Therefore,
the new treatment strategy prescribed was based on the
physicians’ criteria only.
Psychometric evaluations included the Montgomery-
Asberg Depression Rating Scale (MADRS), the Hamil-
ton Anxiety Rating Scale (HARS), and the Clinical
Global Impression - Severity of Illness Scale (CGI-S)
[16,17].Statistical analysis
The analysis presented in this article is focused on the
baseline visit. Patients were allocated to three groups for
analysis according to the new treatment strategy
adopted: switching, augmentation or combination. De-
scriptive statistics were obtained for all variables: mean,
standard deviation (SD) and 95% confidence interval
(CI) for continuous variables, and frequencies and per-
centages for categorical variables.
A multinomial logistic regression was used to explore
the relationship between sociodemographic and clinical
characteristics of the patients and the likelihood of adopt-
ing a specific therapeutic strategy. First, demographic and
clinical characteristics were tested using univariate multi-
nomial logistic regression. Candidate variables with a
p-value≤ 0.2 in the univariate analyses were included in a
backward multivariate multinomial logistic regression pro-
cedure to evaluate which were independently associated
with the treatment strategy adopted by the psychiatrist
after first-line failure. Data analysis was performed using
SAS V.8.02 (SAS, Cary, NC, USA).
Results
A total of 336 patients were included in the study. The
most commonly used strategy was switching antidepres-
sant medication (N= 133, 39.6%). Meanwhile, 80 (23.8%)
patients were allocated to a combination therapy, 60
(17.9%) to an augmentation strategy and 63 (18.8%) to
mixed strategies.
The present analysis was conducted on those patients
that started a switching, a combination or an augmenta-
tion strategy (N = 273). The mean age of this sample was
46.8 years (SD 10.7), and 67.8% were female (Table 1).
The mean MADRS total score was 32.1 (95%CI 31.2-
32.9). The most common AD medications at baseline
were: venlafaxine (15.2%), escitalopram (10.9%), and par-
oxetine (9.8%). The mean duration of baseline AD treat-
ment was 12 weeks (95%CI 10.6-13.3). A change to an
SNRI or an SSRI were the most frequent switching
options (63.9% and 25%, respectively). Most typical com-
binations consisted of an SSRI plus an SNRI (50%), mir-
tazapine (19.3%), or bupropion (11.4%). Atypical
antipsychotic drugs were the most commonly used
agents for augmenting antidepressant effect (N = 46/60,
76.6%). The clinical characteristics of the whole sample
and of each study group are summarized in Table 2.
Patients allocated to an augmentation strategy pre-
sented a worse clinical profile than those allocated to
switching or combination therapies in terms of propor-
tion of patients with psychotic symptoms, number of
previous depressive episodes and hospitalizations, and
MADRS item 10 score (Table 2).
Sociodemographic and clinical variables with a p-value≤
0.2 in the univariate analyses were included in the
Table 1 Sociodemographic characteristics of the sample
Switching Combination Augmentation Total
(N= 133) (N = 80) (N= 60) (N = 273)
Age (years), mean (95%CI) 46.5 (44.5-48.4) 45.9 (43.4-48.1) 49.0 (46.5-51.4) 46.8 (45.5-48.1)
Sex (female), n (%) 92 (69.2) 53 (66.3) 40 (66.7) 185 (67.8)
Marital status, n (%)
Single 16 (12.0) 11 (13.8) 14 (23.3) 41 (15.0)
Married 80 (60.2) 48 (60.0) 35 (58.3) 163 (59.7)
Divorced or separated 37 (27.8) 21 (26.3) 11 (18.3) 69 (25.3)
Education level, n (%)
No education/ Primary education 78 (58.7) 46 (57.5) 41 (68.3) 165 (60.4)
Secondary/ University education 55 (41.4) 34 (42.5) 19 (31.7) 108 (39.6)
Family structure, n (%)
Living alone 17 (12.8) 8 (10.0) 11 (18.3) 36 (13.2)
Couple family 17 (12.8) 18 (22.5) 8 (13.3) 43 (15.8)
Parental family 13 (9.8) 9 (11.3) 11 (18.3) 33 (12.1)
Own family 86 (64.7) 45 (56.3) 30 (50.0) 161 (59.0)
Socioeconomic status, n (%)
Low/Low-Middle 55 (41.4) 30 (37.5) 23 (38.3) 108 (39.6)
Middle 62 (46.6) 40 (50.0) 31 (51.7) 133 (48.7)
Middle-High 16 (12.0) 10 (12.5) 6 (10.0) 32 (11.7)
Work status, n (%)
Active 79 (59.4) 50 (62.5) 20 (33.3) 149 (54.6)
Unemployed 39 (29.3) 19 (23.8) 20 (33.3) 78 (28.6)
Retired/Pensioner 15 (11.3) 11 (13.8) 20 (33.3) 46 (16.9)
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likely influence on treatment decisions. Only two variables
were statistically significant in the multivariate analysis:
the presence of psychotic symptoms and the number of
previous major depressive episodes (Table 3). PatientsTable 2 Clinical characteristics of the sample
Switching
(N= 133)
Number of previous depressive episodes, mean (95%CI) 1.8 (1.5-2.1)
Previous hospitalization, n (%) 12 (9.0)
Previous suicide attempt, n (%) 20 (15.2)
Family history of psychiatric disorders, n (%) 56 (42.1)
Duration of AD treatment (weeks), mean (95%CI)* 12.7 (10.7-14
Presence of psychotic symptoms, n (%) 3 (2.3)
MADRS total score, mean (95%CI) 31.5 (30.3-32
MADRS Item 10 (suicidality) score, mean (95%CI) 2.0 (1.7-2.2)
HARS total score, mean (95%CI) 24.3 (23.1-25
CGI-S score, mean (95%CI) 4.5 (4.3-4.6)
*Antidepressant treatment for the current MDD episode at enrolment.
MADRS, Montgomery-Asberg Depression Rating Scale; HARS, Hamilton Anxiety Ratiwith psychotic symptoms and a higher number of previ-
ous major depressive episodes were more likely to receive
an augmentation strategy (using combination strategy as
reference group). Thus, the odds ratio (OR) to receive an
augmentation strategy was 3.25 (95%CI: 1.02-10.31) inCombination Augmentation Total
(N = 80) (N= 60) (N = 273)
2.0 (1.5-2.4) 3.5 (2.5-4.4) 2.2 (1.9-2.5)
10 (12.5) 15 (25.0) 37 (13.6)
17 (21.3) 16 (26.7) 53 (19.5)
44 (55.0) 30 (50.0) 130 (47.6)
.6) 10.6 (9.1-12.1) 12.2 (8.3-16) 12.0 (10.6-13.3)
5 (6.3) 11 (18.3) 19 (7.0)
.6) 32.5 (30.9-34.1) 32.8 (30.9-34.6) 32.1 (31.2-32.9)
2.3 (2.0-2.6) 2.5 (2.2-2.7) 2.2 (2.0-2.3)
.6) 24.0 (22.3-25.6) 23.0 (21.5-24.5) 24.0 (23.1-24.7)
4.7 (4.5-4.8) 4.7 (4.5-4.9) 4.6 (4.5-4.6)
ng Scale; CGI-S, Clinical Global Impression – Severity scale.
Table 3 Independent factors associated with treatment
patterns after an inadequate antidepressant response
Odds ratio 95% CI p*
Presence of psychotic symptoms
Switch 0.34 0.08 to 1.48 0.152
Augmentation 3.25 1.02 to 10.31 0.045
Number of major depressive episodes
Switch 0.96 0.83 to 1.11 0.558
Augmentation 1.23 1.07 to 1.43 0.005
*Results of multivariate multinomial logistic regression. Combination strategy
was used as reference group in the analysis.
Garcia-Toro et al. BMC Psychiatry 2012, 12:143 Page 4 of 6
http://www.biomedcentral.com/1471-244X/12/143patients with psychotic symptoms and 1.23 (95%CI: 1.07-
1.43) for each previous major depressive episode.
Discussion
According to prior studies, the choice of initial anti-
depressant medication may be influenced by patient
characteristics such as older age, illness severity, prior
suicide attempts, and presence of a comorbid anxiety
disorder [18]. The question of how to proceed with the
next step after initially unsuccessful AD treatment is
crucial. In our study, switching to a different antidepres-
sant drug was the most common strategy used to treat
MDD patients with an inadequate response to first-line
treatment (39.6%).
The clinicians’ preference for switching to a different
antidepressant has previously been described [19]. Cur-
rently, there is not enough clinical evidence to make a
clear recommendation about the best next-step treat-
ment in non-responders. However, changing to another
class of antidepressant is a favoured option, although the
change to another SSRI or to a tricyclic agent could also
be used [19,20]. The lower number of drugs involved
with switching strategies could avoid potential interac-
tions and assure treatment adherence [12]. Such advan-
tages of switching over the two other strategies may
explain its preference among psychiatrists.
Despite the lack of clear evidence-based recommenda-
tions, we observed that some clinical characteristics seem
to have been considered by psychiatrists when they
decided to adopt a new pharmacological approach. Thus,
an augmentation strategy seemed to be the preferential
therapeutic option for patients with a worse clinical pro-
file. According to the multivariate analysis in our study,
patients with more previous depressive episodes and/or
psychotic symptoms were more likely to receive augmen-
tation therapy. No randomized controlled trials have dir-
ectly compared switching and augmentation strategies.
The most valuable evidence comes from the Sequenced
Treatment Alternatives to Relieve Depression (STAR*D)
trial, a four-level study that evaluated different strategies
in non-responders [21]. The results of a retrospectiveanalysis comparing switching and augmentation strat-
egies in patients participating in the STAR*D trial has re-
cently been published [22]. Such analysis showed that
patients who complete initial treatment of 12 weeks or
more and have a partial response with residual mild de-
pressive symptoms may benefit more from augmentation
than switching.
The STAR*D trial also showed that patients with
longer depressive episodes were less likely to achieve re-
mission [21]. Guidelines drawn up by scientific associa-
tions on the management of MDD patients recommend
that, when remission is not achieved with an AD after 6
to 8 weeks of treatment at an adequate dose, this should
be changed [5,20,23]. The timing of adopting a new
pharmacological approach in our study was greater than
recommended: mean duration of AD treatment at base-
line was 12.0 weeks (SD 11.1). The variability observed
by psychiatrists in their clinical attitude towards patients
with major depression has previously been described at
primary care level [24,25]. A recent publication by Chang
et al. found little active management among MDD
patients treated in primary care centres in the USA [26].
General practitioners were not more likely to adjust ther-
apy, even when feedback regarding their patients´ symp-
toms indicated an inadequate response [26].
The fact that approximately one half of patients do
not respond to first-line treatment with antidepressants
constitutes a major concern for psychiatrists in daily
clinical practice [12,27].
Although widely used and usually safe, the efficacy of
even the most widely prescribed combinations of antide-
pressants has not been established by properly controlled
clinical trials [14]. Among patients who did not achieve
remission with initial citalopram treatment in the
STAR*D trial, approximately one-third of patients aug-
menting treatment and one-quarter of patients switching
antidepressant achieved subsequent remission [3].
Lithium is one of the oldest agents used to improve
clinical outcomes in patients with inadequate responses
from antidepressant trials [12]. However, in our study
only 5 patients received lithium (8.3% among the total of
augmentation strategies). The adverse event profile, low
serum therapeutic index, and long-term risks of thyroid
and renal compromise associated with this drug might
explain its poor uptake in our sample [4]. Among the
different augmentation strategies, augmentation with
atypical antipsychotics has been the most studied ap-
proach over recent years. The use of adjunctive atypical
antipsychotic drugs is the strategy with the largest evi-
dence for AD non-responders with a pooled remission
rate of approximately 47% [13]. However, the potential
benefits of these medications must be weighed up
against their known acute and long-term risks, such as
extrapyramidal symptoms and metabolic side effects [4].
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150 mg/d and 300 mg/d had significantly higher risks
for sedation: the numbers needed to treat to harm
(NNTH) were 9 and 7, respectively [28]. Aripiprazole
adjunctive therapy to antidepressants resulted in a sig-
nificantly higher risk for akathisia relative to placebo
(NNTH of 5, 95%CI 4–7) [28]. In addition, fluoxetine
plus olanzapine resulted in significantly greater weight
gain and increase in total cholesterol compared with flu-
oxetine monotherapy [4].
The present manuscript has several limitations. First,
our study analyzed a total of 273 patients and probably
this small sample size could have limited the finding of
additional associations. Second, we only analyzed outpa-
tients receiving care from psychiatrists. Therefore, our
findings may neither generalize to mild depressive
patients, mainly managed in a primary care setting, nor
the inpatient population. Third, comorbidity, ethnicity,
and adverse events associated with the first antidepres-
sant were not assessed, which may also be relevant fac-
tors affecting MDD management.
Conclusions
In our study, the switch to another antidepressant was
the most common therapeutic approach (39.6%) per-
formed by psychiatrists. The number of previous epi-
sodes and the presence of psychotic symptoms were
associated with the adoption of augmenting with a non-
antidepressant agent.
However, limited evidence is available to guide clinical
decision making after initial treatment failure. The iden-
tification of factors related to the efficacy of a specific
treatment would offer clinicians the opportunity to more
adequately select patients who are eligible for such strat-
egy. Further studies are needed to help determine
evidence-based options for the management of MDD
patients after an inadequate response to first-line anti-
depressant treatment.
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